171 related articles for article (PubMed ID: 16026326)
21. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
22. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
23. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
24. A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
Oh KS; Lee S; Yi KY; Seo HW; Koo HN; Lee BH
J Pharmacol Exp Ther; 2009 Jan; 328(1):10-8. PubMed ID: 18836068
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of poly(adp-ribose) polymerase reduces cardiomyocytic apoptosis after global cardiac arrest under cardiopulmonary bypass.
Yeh CH; Chen TP; Lee CH; Wu YC; Lin YM; Jing Lin P
Shock; 2006 Feb; 25(2):168-75. PubMed ID: 16525356
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
Beneke S; Diefenbach J; Bürkle A
Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
[TBL] [Abstract][Full Text] [Related]
27. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
28. Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia.
Takahashi K; Pieper AA; Croul SE; Zhang J; Snyder SH; Greenberg JH
Brain Res; 1999 May; 829(1-2):46-54. PubMed ID: 10350529
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-ribose)polymerase inhibition - where now?
Woon EC; Threadgill MD
Curr Med Chem; 2005; 12(20):2373-92. PubMed ID: 16181138
[TBL] [Abstract][Full Text] [Related]
30. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
[TBL] [Abstract][Full Text] [Related]
31. Poly(ADP-ribosyl)ation and stroke.
Chiarugi A
Pharmacol Res; 2005 Jul; 52(1):15-24. PubMed ID: 15911330
[TBL] [Abstract][Full Text] [Related]
32. Role of poly(ADP-ribose) polymerase during vascular reconstruction.
Albadawi H; Crawford RS; Atkins MD; Watkins MT
Vascular; 2006; 14(6):362-5. PubMed ID: 17150157
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose) polymerase inhibition prevents reactive oxygen species induced inhibition of aldehyde dehydrogenase2 activity.
Wei SJ; Xing JH; Wang BL; Xue L; Wang JL; Li R; Qin WD; Wang J; Wang XP; Zhang MX; Chen YG
Biochim Biophys Acta; 2013 Mar; 1833(3):479-86. PubMed ID: 23159776
[TBL] [Abstract][Full Text] [Related]
34. PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation.
Cieślar-Pobuda A; Saenko Y; Rzeszowska-Wolny J
Mutat Res; 2012 Apr; 732(1-2):9-15. PubMed ID: 22321899
[TBL] [Abstract][Full Text] [Related]
35. Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator.
Laudisi F; Sambucci M; Pioli C
Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):326-33. PubMed ID: 21476963
[TBL] [Abstract][Full Text] [Related]
36. Poly (ADP-ribose) polymerase, nitric oxide and cell death.
Pieper AA; Verma A; Zhang J; Snyder SH
Trends Pharmacol Sci; 1999 Apr; 20(4):171-81. PubMed ID: 10322503
[TBL] [Abstract][Full Text] [Related]
37. Development of PARP inhibitors in oncology.
Rodon J; Iniesta MD; Papadopoulos K
Expert Opin Investig Drugs; 2009 Jan; 18(1):31-43. PubMed ID: 19053880
[TBL] [Abstract][Full Text] [Related]
38. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
39. BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase.
Szabados E; Literati-Nagy P; Farkas B; Sumegi B
Biochem Pharmacol; 2000 Apr; 59(8):937-45. PubMed ID: 10692558
[TBL] [Abstract][Full Text] [Related]
40. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Pacher P; Liaudet L; Mabley JG; Cziráki A; Haskó G; Szabó C
Int J Mol Med; 2006 Feb; 17(2):369-75. PubMed ID: 16391839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
